Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Glaukos Corporation < Previous 1 2 Next > Glaukos Submits New Drug Application to U.S. FDA for iDose TR February 27, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results February 22, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the Citi Healthcare Conference February 15, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22 February 01, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability January 10, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs January 10, 2023 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the J.P. Morgan Healthcare Conference December 28, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the Stephens Annual Investment Conference November 07, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Corporation Announces Third Quarter 2022 Financial Results November 02, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2 October 12, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting September 28, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles September 07, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide September 06, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the Wells Fargo Healthcare Conference August 24, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces FDA 510(k) Clearance of iStent infinite® August 03, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Corporation Announces Second Quarter 2022 Financial Results August 03, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 July 13, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the William Blair Growth Stock Conference June 02, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium May 20, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Corporation Announces First Quarter 2022 Financial Results May 04, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting April 21, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces the Release of its 2021 Sustainability Report April 20, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4 April 13, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy March 14, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results February 22, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces Executive Leadership Changes February 07, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22 February 01, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia January 11, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease January 11, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study January 11, 2022 From Glaukos Corporation Via Business Wire Tickers GKOS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.